Neurofibrillary degeneration can be arrested in an in vivo cellular model of human tauopathy by application of a compound which inhibits tau filament formation in vitro Garth F. HallSangmook LeeJun Yao Lead Discovery And Optimization Pages: 251 - 260
Discovery of compounds that will prevent tau pathology Kenneth S. KosikJae AhnLi-An Yeh Lead Discovery And Optimization Pages: 261 - 266
Cdk5 as a drug target for the treatment of Alzheimer’s disease Lit-Fui LauPatricia A. SeymourJoel B. Schachter Lead Discovery And Optimization Pages: 267 - 273
Tau neurofibrillary pathology and microtubule stability Mary L. MichaelisRick T. DobrowskyGuibin Li Lead Discovery And Optimization Pages: 289 - 293
p38 mitogen activated protein kinase as a therapeutic target for Alzheimer’s disease Stacie A. Dalrymple Lead Discovery And Optimization Pages: 295 - 299
Neuroprotective properties of valproate Rebekah LoyPierre N. Tariot Preclinical Proof Of Concept Pages: 301 - 307
Cellular models for tau filament assembly Li-wen KoMichael DeTureShu-Hui Yen High Throughput Screening Models Pages: 309 - 316
Organotypic slice cultures from transgenic mice as disease model systems Karen DuffWendy NobleYasuji Matsuoka High Throughput Screening Models Pages: 317 - 320
In vivo brain imaging of tangle burden in humans Gary W. SmallEric D. AgdeppaJorge R. Barrio Clinical Development Pages: 321 - 327
Tau as a drug target in Alzheimer’s disease Illana Gozes Comment From The Editor-In-Chief Pages: 337 - 338
